Transcode Therapeutics Inc
RNAZ7.380USD
-0.150-1.99%
收盘 12/24, 13:00（美东）报价延迟15分钟
6.15M总市值
亏损市盈率 TTM
关于 Transcode Therapeutics Inc 公司
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
Transcode Therapeutics Inc简介
公司代码RNAZ
公司名称Transcode Therapeutics Inc
上市日期Apr 28, 2021
CEOCalais (Philippe P)
员工数量7
证券类型Ordinary Share
年结日Apr 28
公司地址6 Liberty Square
城市BOSTON
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编02109
电话18573016857
网址https://www.transcodetherapeutics.com/
公司代码RNAZ
上市日期Apr 28, 2021
CEOCalais (Philippe P)
Transcode Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Thomas A. (Tom) Fitzgerald
Mr. Thomas A. (Tom) Fitzgerald
Chief Financial Officer, Vice President, Director
Chief Financial Officer, Vice President, Director
2.00
--
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
1.00
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Thomas A. (Tom) Fitzgerald
Mr. Thomas A. (Tom) Fitzgerald
Chief Financial Officer, Vice President, Director
Chief Financial Officer, Vice President, Director
2.00
--
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
1.00
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
CK Life Sciences International Holdings, Inc.
9.08%
DRW Securities, LLC
1.28%
The Vanguard Group, Inc.
0.71%
Geode Capital Management, L.L.C.
0.54%
Citi Investment Research (US)
0.17%
其他
88.22%
持股股东
持股股东
占比
CK Life Sciences International Holdings, Inc.
9.08%
DRW Securities, LLC
1.28%
The Vanguard Group, Inc.
0.71%
Geode Capital Management, L.L.C.
0.54%
Citi Investment Research (US)
0.17%
其他
88.22%
股东类型
持股股东
占比
Corporation
9.08%
Investment Advisor
1.99%
Investment Advisor/Hedge Fund
0.54%
Research Firm
0.28%
Individual Investor
0.14%
Hedge Fund
0.02%
其他
87.95%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
37
40.93K
4.61%
-48.04K
2025Q2
41
77.84K
18.97%
+69.48K
2025Q1
45
80.09K
9.69%
+74.47K
2024Q4
36
155.76K
22.37%
+143.23K
2024Q3
40
10.06K
1.97%
-8.53K
2024Q2
41
8.22K
4.45%
-5.03K
2024Q1
41
12.92K
7.67%
+11.92K
2023Q4
41
826.00
4.24%
+40.00
2023Q3
39
727.00
50.61%
+276.00
2023Q2
40
361.00
37.13%
+105.00
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
6.54K
0.79%
--
--
Aug 31, 2025
Geode Capital Management, L.L.C.
4.50K
0.54%
+1.15K
+34.37%
Aug 31, 2025
Tracy (Thomas Joseph)
1.25K
0.15%
+1.25K
--
Mar 07, 2025
Tower Research Capital LLC
402.00
0.05%
+347.00
+630.91%
Jun 30, 2025
SBI Securities Co., Ltd.
10.00
0%
-3.00
-23.08%
Jun 30, 2025
BofA Global Research (US)
8.00
0%
+8.00
--
Jun 30, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Apr 16, 2025
Merger
28→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Jan 11, 2024
Merger
40→1
公告日期
类型
比率
Apr 16, 2025
Merger
28→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Jan 11, 2024
Merger
40→1
Jan 11, 2024
Merger
40→1
Jan 11, 2024
Merger
40→1
Jan 11, 2024
Merger
40→1
May 22, 2023
Merger
20→1
查看更多
常见问题
Transcode Therapeutics Inc的前五大股东是谁？
Transcode Therapeutics Inc 的前五大股东如下：
The Vanguard Group, Inc.持有股份：6.54K，占总股份比例：0.79%。
Geode Capital Management, L.L.C.持有股份：4.50K，占总股份比例：0.54%。
Tracy (Thomas Joseph)持有股份：1.25K，占总股份比例：0.15%。
Tower Research Capital LLC持有股份：402.00，占总股份比例：0.05%。
SBI Securities Co., Ltd.持有股份：10.00，占总股份比例：0.00%。
The Vanguard Group, Inc.持有股份：6.54K，占总股份比例：0.79%。
Geode Capital Management, L.L.C.持有股份：4.50K，占总股份比例：0.54%。
Tracy (Thomas Joseph)持有股份：1.25K，占总股份比例：0.15%。
Tower Research Capital LLC持有股份：402.00，占总股份比例：0.05%。
SBI Securities Co., Ltd.持有股份：10.00，占总股份比例：0.00%。
Transcode Therapeutics Inc的前三大股东类型是什么？
Transcode Therapeutics Inc 的前三大股东类型分别是：
CK Life Sciences International Holdings, Inc.
DRW Securities, LLC
The Vanguard Group, Inc.
CK Life Sciences International Holdings, Inc.
DRW Securities, LLC
The Vanguard Group, Inc.
有多少机构持有Transcode Therapeutics Inc(RNAZ)的股份？
截至2025Q3，共有37家机构持有Transcode Therapeutics Inc的股份，合计持有的股份价值约为40.93K，占公司总股份的4.61%。与2025Q2相比，机构持股有所增加，增幅为-14.35%。
哪个业务部门对Transcode Therapeutics Inc的收入贡献最大？
在--，--业务部门对Transcode Therapeutics Inc的收入贡献最大，创收--，占总收入的--%。
